You just read:

Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference

News provided by

Pieris AG

15 Nov, 2011, 10:00 GMT